Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Takeda gets EU approval for ALUNBRIG in ALK+ NSCLC
The latest approval from the European Commission (EC) authorises ALUNBRIG to be used as a monotherapy for the treatment of adults having anaplastic lymphoma kinase-positive (ALK+) advanced non-small
The latest approval from the European Commission (EC) authorises ALUNBRIG to be used as a monotherapy for the treatment of adults having anaplastic lymphoma kinase-positive (ALK+) advanced non-small
In addition, the companies have completed a cross-license of their respective intellectual property for Alnylam’s lumasiran and Dicerna’s nedosiran investigational programs for the treatment of primary hyperoxaluria (PH).
The late-stage trial met both the co-primary endpoints, with Nucala added to standard of care delivering statistically significant improvements in the size of nasal polyps at week 52
BioArdis will retain all rights to the licensed product in the rest of the world. BIO-1262 is being evaluated as a potential new treatment for hepatocellular carcinoma (HCC)
This expansion includes up to three additional targets focused on host factors for SARS-CoV-2, including ACE2 and TMPRSS2, both of which are considered critical for viral entry, with
Zymeworks will receive a payment under its collaboration with BeiGene as a result of the achievement of this development milestone. “To date, ZW25 has demonstrated promising activity in
The parties, which have signed a partnership and license agreement, have agreed to discover, develop, manufacture, and commercialise fully human neutralising monoclonal antibodies to address the COVID-19 pandemic.
The submission is based on results from the pivotal Phase 2 KarMMa study. The KarMMa study evaluated the efficacy and safety of ide-cel in heavily pre-treated patients with
The company has initiated an additional research and development project targeting the coronavirus group and has wrapped up initial screening under the repurposed and new drug discovery platform
The approval by the US Food and Drug Administration was based on positive results from the Phase III CASPIAN trial showing IMFINZI in combination with SoC platinum-etoposide demonstrated a